Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis (FETEM)

Inclusion Criteria: Expanded Disability Status Scale mark 1.5 - 4.5 Fatigue Severity Scale > 4 Beck Depression Inventory < 30 No relapse for, at least, three month prior to screening Drug washout period = 4 weeks for any fatigue aimed drug Patient capable to sign the informed consent Exclusion Criteria: Fatigue causing disease other than multiple sclerosis: sleep apnea other autoimmune disease that could be explain the fatigue. endocrine autoimmune disease if the blood test is not in range in the last 6 month. patient with diagnosis of chronic fatigue Patient with high blood pressure out of range or decompensated heart failure or New York Heart Association (NYHA) 3-4. Secondary Epilepsy or neuropathic chronic pain which requires continuous treatment. Contraindication for trial treatment: Some kind of magnetic metal. Epilepsy antecedents. Any drugs that could decrease the seizure threshold Amantadine sensitivity Cardiopathy disease, severe kidney failure, Angle-closure glaucoma Breastfeeding, pregnancy, or pregnancy planning phase in the next year. Of childbearing potential and willing to use an acceptable method of contraception during the study period. Patient with a terminal disease with no more than one year life expectancy. Patient has been treated for a maligned disease in the past three years. A scheduled surgery in the course of the trials. Any condition that a member of research team consider could affect to participation/follow up patient. Alcoholic o toxics condition in the last year. Major mental disorders Poor communication skills or poor cognitive condition. Other trial participation in the previous 4 month. Use a chronic drug that could interfere in the clinical outcome.